Senior Director, Clinical Research - Neurodegeneration
Alnylam Pharmaceuticals | |
United States, Massachusetts, Cambridge | |
Sep 15, 2026 | |
|
Overview Alnylam Pharmaceuticals is seeking an imaginative physician drug developer. This is an opportunity to provide clinical leadership in developing RNAi therapeutics in Alnylam's rapidly expanding portfolio, which spans the areas of rare genetic diseases, cardio-metabolic diseases, neuroscience, hematology and hepatology. The successful candidate's primary role will be to drive the pipeline forward through leadership of clinical development programs. While the primary focus responsibility will be as clinical lead physician on Alnylam's Huntington's program, the role may support across a range of therapeutic areas and all stages of development may be required as pipeline assets evolve. The Sr. Director is expected to play a leading and influencing role in the overall clinical development strategies and drive progress and operational excellence for associated clinical trials. In addition, this role will include interaction with Alnylam's research group, helping to advise the team on the clinical development feasibility of novel targets and the design of proof-of-concept studies. This work will also involve extensive consultation and collaboration with external experts. It is expected that additional opportunities will arise to lead bench-to-bedside early phase clinical development programs. The Senior Director, Clinical Research, will work in a matrix organization across Regulatory, Biostatistics, Clinical Operations, Preclinical, Commercial & QA teams to ensure fully harmonized and integrated development strategies. They will be a key Alnylam Development spokesperson at external meetings, including regulatory interactions and scientific meetings. This position is hybrid and will be primarily located at our Cambridge, MA headquarters or Maidenhead, UK location. Key Responsibilities
Qualifications
About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Before applying, please review Alnylam's CandidatePrivacy Noticeregarding how Alnylam handles Personal Data you provide with your application for employment. | |
Sep 15, 2026